Airsupra Access in 2026: A Provider Briefing

Airsupra (Albuterol 90 mcg/Budesonide 80 mcg) represents a meaningful advance in asthma management — the first FDA-approved rescue inhaler that combines a short-acting beta-agonist with an inhaled corticosteroid. For prescribers, it offers an opportunity to address both acute bronchoconstriction and underlying airway inflammation with a single as-needed device.

However, since its commercial launch in 2024, providers and patients have encountered consistent access challenges. This briefing summarizes the current availability landscape, prescribing implications, and practical strategies for helping patients obtain Airsupra in 2026.

Timeline and Background

• January 10, 2023: FDA approval of Airsupra for as-needed treatment or prevention of bronchoconstriction and reduction of exacerbation risk in adults ≥18 with asthma
• Early 2024: Commercial launch and initial pharmacy distribution
• March 2024: AstraZeneca announced $35/month out-of-pocket cap for commercially insured patients across its inhaled respiratory portfolio
• October 2025: Launch of AstraZeneca Direct — a direct-to-patient home delivery platform offering Airsupra at approximately $249 per inhaler
• January 2026: Continued formulary expansion; Airsupra now covered on an increasing number of commercial and Medicaid plans

Prescribing Implications

Indication and Dosing

Airsupra is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma aged 18 and older. The recommended dose is 2 inhalations as needed, with a maximum of 6 doses (12 inhalations) per 24 hours.

Key clinical considerations:

• Airsupra is a rescue inhaler — it is not intended to replace daily maintenance therapy
• Patients should continue their prescribed controller medications (ICS, ICS/LABA, biologics)
• The addition of Budesonide to the rescue dose provides anti-inflammatory action at the point of symptom onset, aligning with GINA recommendations for anti-inflammatory reliever therapy
• Patients should rinse their mouth after use to minimize oral candidiasis risk

Patient Selection

Airsupra may be most appropriate for:

• Adult patients with persistent asthma who frequently use their rescue inhaler
• Patients with a history of exacerbations despite maintenance therapy
• Patients who may benefit from corticosteroid delivery at the point of rescue
• Patients who are adherent to as-needed regimens but inconsistent with daily controllers

It is not approved for children under 18 and should be used with caution in patients with cardiovascular disorders, seizure disorders, thyrotoxicosis, diabetes, or hepatic impairment.

Drug Interactions

Key interactions to monitor (see our detailed post on Airsupra drug interactions):

• Beta-blockers: May block pulmonary effects of Albuterol and produce severe bronchospasm — avoid concurrent use when possible
• MAO inhibitors and tricyclic antidepressants: Use with extreme caution; may potentiate cardiovascular effects of Albuterol
• Strong CYP3A4 inhibitors (Ketoconazole, Ritonavir, Itraconazole, Clarithromycin): May increase systemic Budesonide exposure
• Non-potassium-sparing diuretics: May worsen Albuterol-induced hypokalemia
• QTc-prolonging agents: Theoretical increased arrhythmia risk with concurrent Albuterol use

Current Availability Picture

As of March 2026, Airsupra is not on the FDA's drug shortage list. AstraZeneca maintains adequate manufacturing supply. The access barrier is primarily at the pharmacy stocking level:

• Many chain pharmacies (CVS, Walgreens, Walmart) do not routinely stock Airsupra due to its high retail cost ($500-$737) and relatively low prescription volume compared to generic Albuterol
• Independent pharmacies are generally more willing to special-order (1-2 business day turnaround)
• Specialty and mail-order pharmacies typically maintain more consistent stock

Provider tools like Medfinder for Providers can help you identify which pharmacies near your patients currently have Airsupra in stock.

Cost and Access Landscape

Pricing

• Retail (WAC): $500-$737 per inhaler
• AstraZeneca Direct: ~$249 per inhaler (home delivery, cash pay)
• Coupon cards (SingleCare, GoodRx): $400-$500 range
• SUPRA Savings Card: As low as $0 for commercially insured patients (max $130 savings per fill)
• AstraZeneca $35/month cap: Applies to commercially insured patients across AZ respiratory portfolio

Insurance Coverage

Coverage has expanded significantly since launch but remains inconsistent:

• Most commercial plans and Medicaid programs now include Airsupra, though many require prior authorization or step therapy (documented failure of Albuterol-only rescue)
• Some plans have excluded Airsupra from formulary, requiring appeals or peer-to-peer review
• Medicare Part D coverage varies by plan; some patients may qualify for AZ&Me assistance

Patient Assistance

• AZ&Me Prescription Savings Program: Provides Airsupra at no cost to eligible uninsured patients or Medicare patients meeting Federal Poverty Level guidelines. E-prescribe directly to AZ&Me's pharmacy for fastest processing.
• Phone: 1-866-480-0030
• Website: azandmeapp.com

Tools and Resources for Providers

1. Medfinder for Providers — Real-time pharmacy stock search to identify where patients can fill Airsupra prescriptions nearby
2. AstraZeneca Direct — Direct patients to this home delivery program for a cash price of ~$249
3. SUPRA Savings Card — Enroll patients at airsupra.com/savings-card for potential $0 copay
4. Prior Authorization Support — AstraZeneca's HCP portal (airsuprahcp.com) provides PA support tools and clinical documentation templates
5. E-Prescribing to AZ&Me — For uninsured patients, e-prescribe directly to AZ&Me's partner pharmacy for fastest fulfillment

Looking Ahead

Several developments may improve Airsupra access in the coming months:

• Formulary expansion continues: AstraZeneca is actively negotiating with additional payers
• AstraZeneca Direct platform growth: The direct-to-patient model bypasses pharmacy stocking issues entirely
• Clinical guideline alignment: As GINA and NAEPP guidelines increasingly support anti-inflammatory reliever therapy, payer coverage is likely to follow
• No generic expected near-term: Patent protections remain in place, with no generic competition anticipated for several years

Final Thoughts

Airsupra fills an important gap in asthma management by combining rescue bronchodilation with anti-inflammatory action. While the access landscape has improved since launch, providers should be prepared to navigate prior authorization requirements, counsel patients on savings programs, and direct them to pharmacies that stock the medication.

Medfinder for Providers is a free tool designed to help your practice locate medications in stock for patients. For more clinical details, see our posts on how Airsupra works and Airsupra side effects.

For a practical guide on helping patients fill their prescriptions, see how to help your patients find Airsupra in stock.